nRichDX has launched its Revolution system, a high-yield sample prep IVD platform that delivers exponentially more target input for molecular assays, increasing the sensitivity of liquid biopsy-based tests.
Revolution's increase in target yield is accomplished by combining the ability to process a wide range of sample volumes, from 3 mL to 50 mL, with high recovery rates of 70% to 90%.
The system's initial use involves the extraction of cell-free DNA (cfDNA) from plasma and urine with applications for circulating tumor cells (CTCs), exosomes, and total cell-free nucleic acid in the development pipeline.
nRichDX will showcase Revolution at the Association for Molecular Pathology (AMP) meeting taking place November 7-9 at the Baltimore Convention Center.
